Login / Signup

Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021.

Manon C W SpaanderRuben D van der BogtTodd H BaronDavid AlbersDaniel BleroAntonella de CeglieMassimo ConioLászló CzakóSimon EverettJuan-Carlos Garcia-PagánAngels GinèsManol JovaniAlessandro RepiciEduardo Rodrigues-PintoPeter D SiersemaLorenzo FuccioJeanin E van Hooft
Published in: Endoscopy (2021)
5: ESGE recommends against the use of SEMSs as first-line therapy for the management of benign esophageal strictures because of the potential for adverse events, the availability of alternative therapies, and their cost. Strong recommendation, low quality evidence. 6: ESGE suggests consideration of temporary placement of self-expandable stents for refractory benign esophageal strictures. Weak recommendation, moderate quality evidence. 7: ESGE suggests that fully covered SEMSs be preferred over partially covered SEMSs for the treatment of refractory benign esophageal strictures because of their very low risk of embedment and ease of removability. Weak recommendation, low quality evidence. 8: ESGE recommends the stent-in-stent technique to remove partially covered SEMSs that are embedded in the esophageal wall. Strong recommendation, low quality evidence. 9: ESGE recommends that temporary stent placement can be considered for the treatment of leaks, fistulas, and perforations. No specific type of stent can be recommended, and the duration of stenting should be individualized. Strong recommendation, low quality of evidence. 10 : ESGE recommends considering placement of a fully covered large-diameter SEMS for the treatment of esophageal variceal bleeding refractory to medical, endoscopic, and/or radiological therapy, or as initial therapy for patients with massive bleeding. Strong recommendation, moderate quality evidence.
Keyphrases
  • antiplatelet therapy
  • high intensity
  • stem cells
  • acute coronary syndrome
  • climate change
  • mesenchymal stem cells